Ovarian Cancer

The European Committee for Medicinal Products for Human Use has recommended approval of olaparib as a frontline maintenance treatment for patients with BRCA-mutant advanced high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response following first-line platinum-based chemotherapy.

Investigational data are associated with folate receptor alpha-targeting agents, with an emphasis on the recent development and therapeutic potential of antibody-drug conjugates for the treatment of patients with ovarian cancer.

Kathleen N. Moore, MD, discusses the potential impact of antibody-drug conjugates on outcomes for patients with ovarian cancer.

Michael Birrer, MD, PhD, discusses the evolution of folate receptor alpha-targeting agents in ovarian cancer.

Multiple agents that target folate receptor alpha have been developed and are currently under investigation for the treatment of patients with ovarian cancer.

Joyce F. Liu, MD, MPH, assistant professor of medicine, Harvard Medical School, and director of clinical research for gynecologic oncology at Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in patients with recurrent ovarian cancer.

Although there are several maintenance strategies to consider for patients with advanced ovarian cancer, the decision of which approach to pursue largely depends on the molecular makeup of an individual patient’s tumor.

Chrisann Kyi, MD, discusses the utility of PARP inhibitors in the primary treatment and maintenance settings for patients with recurrent ovarian cancer and the next steps that lie ahead.

Jason A. Konner, MD, sheds light on the current treatment landscape for patients with platinum-sensitive and platinum-resistant/recurrent ovarian cancer

Britta Weigelt, PhD, discusses germline and somatic mutations in ovarian cancer that confer potential implications on treatment decisions, as well as those that carry an added cancer risk.